Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study concomitant high-dose radio-immuno- and chemotherapy with simultaneous application of Zevalin and BEAM [busulfan, cytarabine, etoposide, melphalan] followed by autologous peripheral stem cell transplantation in relapsed and refractory CD 20+ non-Hodgkin's lymphoma.

Next Previous
X
Search
Trial Profile

Phase I/II study concomitant high-dose radio-immuno- and chemotherapy with simultaneous application of Zevalin and BEAM [busulfan, cytarabine, etoposide, melphalan] followed by autologous peripheral stem cell transplantation in relapsed and refractory CD 20+ non-Hodgkin's lymphoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Busulfan; Cytarabine; Etoposide; Melphalan; Rituximab
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Primary-Effusion-Lymphoma
  • Focus Adverse reactions
  • Acronyms escZ-BEAM

    • Most Recent Events

    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Jun 2008 Preliminary results presented at ASCO 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top